(Reuters) – Alexion Pharmaceuticals has agreed to buy Sweden’s Wilson Therapeutics for 7.1 billion Swedish crowns ($855 million), boosting its line-up of rare disease drugs as a wave of deal-making in the biotechnology sector continues.
https://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.png00Reuters: Health Newshttps://www.teleconsulteurope.com/wp-content/uploads/2014/11/teleconsult-logo-300x124.pngReuters: Health News2018-04-11 19:07:572018-04-11 19:07:57Biotech M&A rolls on as Alexion snaps up Wilson for $855 million